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Abstract 
Myocardial infarction (MI) is a leading cause of death in developed countries. Genetic 
association studies have been applied to search for associations between MI and 
candidate genes. In the present study, genetic variants for two MI candidate genes, 
thrombospondins-4 (THBS4) (29926C>G) and methylenetetrahydrofolate reductase 
(MTHFR) (677C>T and 1298A>C) were genotyped using a large cohort from the 
genetically homogenous Newfoundland population. This study focused on determining 
the distribution of each individual gene variants, and possible intragenic and intergenic 
allelic interactions. Our results suggest that: 1) homozygosity for the THBS4 29926C 
variant is associated with MI, especially in older females; 2) the MTHFR 677T is a weak 
protective factor against MI but its effect is silenced when it is in cis with 1298C; 3) the 
MTHFR 1298C is a risk factor for later onset MI and its effect is reduced when the trans 
configuration with 677T. 
Keywords: 
myocardial infarction, risk factors, association study, thrombospondin-4, Newfoundland 
population, MTHFR 677C>T, MTHFR 1298A>C, Haplotype 
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Chapter 1 
Review of Literature 
1 
1.1 Myocardial Infarction (MI) 
The clinical manifestations of coronary heart disease (CHD) are due to chronic arterial 
obstructions or acute arterial occlusions in various vascular territories, which ultimately 
leads to an inadequate supply of blood to the heart muscle causing ischemia. In some 
cases ischemia may become so severe that it causes a MI. This may result from 
atherosclerosis within the coronary arteries, or the formation of a blood clot. The most 
likely is a combination of both which ultimately leads to necrosis of cardiac muscle cells 
(Ulbricht and Southgate 1991 ). 
Atherosclerosis, can start to develop in childhood and progresses undetected throughout 
life. In a large atherosclerotic plaque, the outermost shell can burst causing slight 
bleeding that can lead to the formation of a thrombus, which can block the vessel 
(Steinberg et al. 2002). Atherosclerosis with arterial wall inflammation involves 
diapedesis of monocytes across the endothelial barrier, and release of a variety of 
cytokines and chemokines (Stratford et al. 1986; Poole and Florey 1958; Lusis 2000; 
Libby 2002). The genetic basis of the process has not yet been deciphered. 
MI remains a leading cause of morbidity and mortality in North America, Europe and 
Asia (Breslow 1997; Braunwald 1997). Moreover, acute myocardial infarction (AMI) is 
now the leading cause of death in Canada, especially among elderly patients (Boucher et 
al. 2001 ). Therefore, prevention of this disease is an important public health goal. One 
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approach to preventing myocardial infarction is to use observational genetic studies to 
identify disease-susceptibility genes, which will further deeper our understanding of the 
etiological pathways ofMI and thus indicate new potential targets for intervention (Tobin 
et al. 2004). 
MI is a complex multifactorial and polygenic disorder. The incidence of MI increases as 
the number of conventional risk factors present, including smoking, high blood pressure, 
high cholesterol, physical inactivity, obesity and diabetes (Psaty et al. 2001; Esteghamati 
et al. 2006; Tonstad and Andrew Johnston 2006). These traditional risk factors have only 
a limited sensitivity among subjects with lows-to-moderate levels of risk, which suggests 
the contribution ofuncharacterized genetic components in susceptibility to MI. 
1.2 Genetic risk factors 
The level at which an individual's genotype contributes to the development of MI is still 
the subject of much debate. The role of inheritance is strongly supported by the predictive 
value of a family history for premature ischemic disease (Roncaglioni et al. 1992; Brenn 
and Njolstad 1998; Becker et al. 1998). A family history of cardiovascular disease (CVD) 
is one of the strongest risk markers for Ml, with relative risk being as high as 3.4 for men 
with two or more affected parents or siblings (Leander et al. 2001 ). Twin studies indicate 
that the heritability of MI is 0.26 in males and 0.60 in females (Wienke et al. 2001; 
Zdravkovic et al. 2002; Nordlie et al. 2005). The mechanisms by which genetic variants 
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contribute to the strong familiarity of CHD are not fully understood, but it is likely the 
disease is influenced by a large number of genetic variants (Tang and Tracy 2001 ). These 
studies support the hypothesis that genetic factors contribute to the development of 
coronary artery disease (CAD) and MI. A high death rate, late-onset characteristics, and 
complications of phenocopy in families also present major challenges to the genetic 
dissection of this important disease (Sing et al. 2003). 
Genetic studies of CAD and MI are lagging behind those of other cardiovascular 
disorders. The major reason for the limited success in the field of CAD/MI genetics is 
that they are complex multifactorial diseases. Genetic association studies have been 
applied to search for relationships associations between MI and various genes whose 
biological function are known to associate with vascular biological pathways. The 
pathways include blood coagulation, inflammation reaction, vascular function, and 
homocysteine metabolism (Wu and Tsongalis 2001; Marcucci et al. 2005). 
Gene mutations in several metabolic pathways (lipoprotein metabolism, coagulation and 
inflammation) may lead to overproduction or underproduction of key proteins and hence 
upset the delicate balance of homeostasis. Intermediate phenotypes such as hypertension, 
diabetes, and obesity interact to modulate the risk for CHD. Figure 1 summarizes the role 
of some of the key candidate genes and intermediate traits involved in CHD (Stephens 
and Humphries 2003). 
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Outcomes of most association studies are highly contradictory and controversial, which 
reflects the complicated nature of genetic involvement in MI. Genetic predisposition in 
MI results from the co-effect of multiple genes, gene-gene and/or gene-environment 
interactions. These collectively produce an additive or synergistic effect which affects 
risk for disease. Individual genetic changes may produce small or insufficient effects to 
impart significant pathogenic risk. Gene-gene interaction as a significant factor in genetic 
predisposition to MI has been clearly demonstrated in previous studies, and genetic 
predisposition for CAD from co-effect of intragenic allelic interaction has also been 
previously reported for other genes (Butt et al. 2003, Xie et al. 2003). 
1.3. Association studies 
Association studies aimed to test whether single-locus alleles, genotype frequencies or 
haplotype frequencies are different between 2 groups (cases and controls). Genetic 
association studies are to determine whether a genetic variant is associated with a disease 
or trait. When a particular allele, genotype or haplotype of a polymorphism or 
polymorphism(s) was seen more often than expected in an individual with the disease, 
the allele or genotype is associated with increased risk of disease. The usual conclusion of 
such studies is that the gene variants being tested either affect risk of disease directly or 
are markers for some nearby genetic variants that affect risk of disease. 
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Figure 1. Pathophysiology, intermediate traits and candidate genes implicated in CHD 
(Stephens and Humphries 2003). 
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Genetic association studies essentially look for correlations between phenotype and 
genotype, aiming to detect association between one or more genetic polymorphism and a 
trait, which might be some quantitative characteristic, discrete attribute or disease. It has 
been realized that genetic susceptibility to common complex disorders probably involves 
many genes, most of which have small effects. This fact, together with the identification 
of large numbers of single nucleotide polymorphisms (SNPs) throughout the genome 
and the rapidly falling genotyping costs, has led to the importance of association studies 
in genetic epidemiology (Risch and Merikangas 1996). An association can be found 
either with functional genetic variants that have biological consequences related to a 
disease or with other variants that are in linkage disequilibrium with these variants. 
Although association studies provide important indirect evidence for genetic effects of a 
particular gene, it is clear from the literature that such studies have serious limitations. 
Thus, one must use caution when drawing conclusions from association studies (Almasy 
and MacCluer 2002; Gambaro et al. 2000). There are now explicit guidelines for 
publishing genetic association studies of complex diseases (Editorial 1999; Cooper et al. 
2002). 
SNPs in candidate genes have been tested for genes associated with myocardial 
infarction. Results from these studies have, in general, not been replicated or indicate 
only a modest risk of myocardial infarction. Case-control association studies have 
identified several genes with variants that are associated with either an increased risk of 
myocardial infarction or a protective effect (Topol et al. 2001; Butt et al. 2003; Wang and 
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Chen 2003; Xie et al. 2003; Shen et al. 2004). Most case-control association studies have 
focused on variants in genes related to known risk factors for coronary heart disease. 
Methodologically, this is the easiest approach by which a candidate gene is selected 
based on its potential involvement in CAD/MI. Some genes associated with MI were 
listed in the Table 1 (Gibbons et al. 2004). 
1.3.1 SNP 
A SNP is the most common type of stable genetic variation in the population. It is a DNA 
sequence variation occurring when a single nucleotide in the genome differs between 
members of a species or between paired chromosomes in an individual. SNPs are found 
throughout the genome (e.g. in exons, introns, intergenic regions, promoters, enhancers, 
etc). A SNP occurs in approximately every 1000 base pairs (Brookes 1999) and has a 
minor allele frequency of greater than 1% in at least one population (Risch, 2000). The 
total number of SNPs in the human genome is estimated to be more than ten million 
(Kruglyak and Nickerson 2001; Botstein and Risch 2003). The high frequency with 
which SNPs are found within the genome allows us to use SNPs as candidate 
polymorphisms to be tested directly as the functional or causal mutations for a disease or 
trait. To avoid doing genotypings that fail to identify disease-causing polymorphisms 
when conducting association studies, it is common to actively select for SNPs that are 
likely to have a direct impact on the disease or other phenotype of interest (Chanock 
2001). 
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Table 1. Selected Genes Associated With MI (Adapted from Gibbons et al. 2004) 
Gene Gene Name Reference 
Symbol 
MMP3 Matrix metalloproteinase 3 T erashima et al. 1999 
LPL Lipoprotein lipase protein Holmer et al. 2000 
CCRS Chemokine (C-C motif) receptor Gonzalez et al. 2001 
APOB Apolipoprotein B Tybjaerg-Hansen et al. 1991 
APOE Apolipoprotein E Batalla et al. 2000 
AGTR1 Angiotensin II type 1 receptor Batalla et al. 2000 
AGT Angiotensinogen Batalla et al. 2000 
ACE Angiotensin I converting enzyme 1 Batalla et al. 2000 
CRP C-reactive protein Margaglione et al. 2000 
FGB Fibrinogen_ chain Zito et al. 1997 
THBD Thrombomodulin Ireland et al. 1997 
PECAMl Platelet-endothelial cell adhesion molecule-1 Sasaoka et al. 2001 
ANP Atrial natriuretic peptide Cho et al. 1999 
BNP Brain natriuretic peptide Cho et al. 1999 
CNP C-type natriuretic peptide Cho et al. 1999 
HSP70A1 Heat shock protein 70-1 Gonzalez et al. 2001 
SELP Selectin P Tregouet et al. 2002 
CD14 CD14 Unkelbach et al. 1999 
9 
1.3.2 Haplotype 
Because new SNP alleles arise as mutations at different loci and at different points in 
time, and because they occur with such great abundance in the genome, groups of 
neighboring SNPs may have alleles that show distinctive patterns of linkage 
disequilibrium (LD). As such, they may create a haplotypic diversity that can be 
exploited in both genetic linkage and direct association studies (Nickerson 1992). 
Haplotype-based analysis could prove a more powerful approach to dissecting the genetic 
architecture of complex diseases. Haplotypes capture information about regions 
descended from ancestral chromosomes. They are essential for many genetic studies, 
especially for association based gene mapping, because they can be much more 
informative than single markers, and they give higher power for assigning a phenotype to 
a genetic region. Being able to use haplotypes is particularly important for SNP markers, 
which individually are relatively uninformative (Cardon and Bell 2001). It is 
demonstrated that only a few SNPs are needed to characterize the most common 
haplotypes occurring within each haplotype block. These are termed tag-SNPs. However, 
tag-SNPs have been discovered in only a small number of genes. In the future, because of 
the application of the haplotype map to delineate these tag-SNPs, haplotype-based 
association analysis are likely to replace single SNP-based analysis (The International 
HapMap Consortium 2003). 
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The HapMap project is currently defining these haplotype blocks in the human genome. 
The aim is to clarify how the human genome is organized into haplotype blocks by 
analyzing the block patterns in blood samples taken from people in Japan, Nigeria, and 
China, as well as from people of northern and western European ancestry in the United 
States. The biggest advantage of this approach is that if common haplotypes capture most 
of the genetic variation across sizable regions, they can be tested with the use of a few tag 
SNPs (Gabriel et al. 2002), potentially providing a powerful shortcut to identifying genes 
for complex traits, including CAD. 
Current practical laboratory techniques provide unphased genotype information for 
diploids, i.e., an unordered pair of alleles for each marker. Reconstruction of haplotypes 
from genotype data is then a crucial step in the analysis process. Tpere are two 
approaches to the problem. One is based on trios: haplotypes are determined from the 
genotypes of a subject's parents. This involves significant additional genotyping costs and 
potential problems in recruiting the parents. Furthermore, in the case of SNPs, on average 
up to 12% of the alleles can still remain ambiguous. The second approach is to use the 
available population sample of genotype data alone, and to apply computational or 
statistical inference to find the most likely haplotype configuration that is consistent with 
the observed genotype data. A number of approaches have been proposed to the 
haplotype inference problem, but currently none of them are targeted at sparse marker 
maps (Lauri et al. 2004). 
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Haplotype analysis has become increasingly common in genetic studies of human 
disease. Much of the attention was aimed at finding the haplotype phase. It is usually 
crucial to estimate correctly the haplotype frequencies in the population and not 
necessarily to phase the individual genotypes. There are, however, a few EM-based 
(Expectation Maximization) algorithms that directly estimate the haplotype frequencies 
(Long et al. 1995; Excoffier and Slatkin 1995; Kuhner et al. 2000; Fallin and Schork 
2000). Those methods try to find a haplotype distribution that maximizes the probability 
of observing genotypes in a given sample, under the assumption of Hardy-Weinberg 
equilibrium. One of the main drawbacks in these methods is that there is no guarantee 
that the algorithm converges to a global maximum, or that the algorithm converges in 
polynomial time. The starting point of the algorithm heavily affected both the 
convergence of the EM algorithm to a global optimum and its running time. However, 
even in the worst case, individual haplotype frequency estimates via the EM algorithm do 
not deviate much beyond 5% of their true value among sample individual for sample size 
bigger than 100 (Fallin and Schork 2000). 
1.3.3 Limitations of candidate gene association studies 
Like all experimental designs and model systems, genetic association studies in human 
samples have strengths and limitations (Schork et al. 2000; Schork et al. 2001 ). These 
statistics make clear the importance of elucidating the genetic basis of CAD, but as 
mentioned previously, this is a difficult area to study. In many cases, genetic associations 
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found in one study are not supported by subsequent studies, which makes the search for 
definitive conclusions problematic. 
The results from the candidate gene association studies should be interpreted with caution 
as many of these studies are compounded by the selection bias of cases and controls, 
population admixture, phenotyping errors, and small sample sizes in some studies. 
Numerous case-control association studies were carried out and variants in many genes 
have been implicated in increasing or decreasing the susceptibility to CAD or MI (Shen 
et al. 2004; Wang and Chen 2003; Butt et al. 2003; Xie et al. 2003). Publication and time-
lag biases are also important considerations. Medical journals and authors both tend to 
select positive, rather than negative, findings for publication. Whereas negative studies 
often take longer time to be published than positive studies (Ioannidis et al. 2001; 
Winkelmann et al. 2000). 
Little is known of gene-gene and gene-environment interactions in CAD, but it would be 
surprising if they were not important (Sing et al. 2003). There have been hundreds of 
association studies for CAD and MI, but most have been underpowered and probably 
represent type 1 errors. A few have been convincingly confirmed (Lusis 2000). Some 
large-scale association studies have been performed with many candidate genes. For 
example, a study of patients from the Cleveland Clinic Foundation examined 62 vascular 
biology candidate genes and observed the significant associations with SNPs of three 
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unlinked genes, all of which are the members of the thrombospondin family (Topol et al. 
2001). 
The slow process of gene identification in complex traits is most likely caused by several 
factors, such as locus and allelic heterogeneity, epistasis, difficulties in assessing the 
complex phenotypes, unknown modes of inheritance, phenocopies, reduced penetrance, 
and a high frequency of disease-predisposing alleles (Lusis et al. 2004). 
Etiologic and genetic heterogeneity underlying the affected status of cases or the 
quantitative trait of interest can obscure the identification of an association, especially in 
small samples, and thus increasing the probability of a false-negative result. One of the 
largest and most common challenges facing case-control studies on possible gene-gene 
interactions is the ethnic heterogeneity of the investigated populations. Newfoundland 
presents an interesting and unusual population structure, which can help to overcome the 
heterogeneity frequently found in other studies. The island ofNewfoundland is located in 
the Atlantic Ocean, off the eastern coast of Canada. The population of the island of 
Newfoundland consists mainly of descendants of English and Irish settlers who arrived in 
the 1 ih and 18th centuries (Bear et al. 1987; Martin et al. 2000). The geographical and 
social isolation of this island has ensured very little inward migration for several hundred 
years and has led to a small population (530 000 individuals; Statistics Canada 2001) with 
a relatively homogenous genetic background, which is ideal for the study of complex 
multifactorial disease such as MI. 
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1.4 Thrombospondins-4 (THBS4) 
THBS4 is one of five members of the THBS family of multidomain extracellular matrix 
proteins with related sequences but diverse tissue distribution. All are structurally related 
and at least four of them (THBS-1, -2, -4 and -5) have been detected in vascular tissue 
(Wight et al. 1985; Lawler et al. 1993; Stenina et al. 2003 ). All are related to a wide 
range of processes involving the vessel wall, including smooth muscle cell proliferation 
(Majack et al. 1986) and migration (Taraboletti et al. 1990), and associated with various 
extracellular matrix proteins (Narouz-Ott et al. 2000). THBS-4 appears to be more 
' 
specific to cardiac and skeletal muscle (Lawler et al. 1993). The variant THBS4 P387 is 
predicted to affect folding and secretion of the protein and disruption of the calcium 
binding site (Bomstein 1992; Geourjon et al. 1994), and may affect the cellular dynamics 
of the vessel wall (Stenina et al. 2003). The inhibitory effects of THBS4 P387 on 
endothelial cell (EC) repair functions, coupled with its stimulatory effects on smooth 
muscle cell (SMCs), may predispose the vasculature to the initiation and development of 
atherosclerotic lesions (Stenina et al. 2003). 
Topol et al. (Topol et al. 2001) studied SNPs in 62 vascular biology genes in more than 
350 families, in which CAD or MI had occurred before age 45 in males and 50 in 
females. They determined that certain variants of thrombospondin genes 
(thrombospondin is a platelet surface protein involved in blood clotting) were associated 
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with either an increased or decreased risk of MI. The 387P variant of THBS4 was most 
strongly associated with an increased risk of MI. Carriers of the P allele had an adjusted 
odds ratio for MI of 1.89 (P = 0.002). However, Topol's group noted that they were 
unable to replicate these findings in two smaller studies (Topol et al. 2001). This result 
was replicated by using a larger number of patients (Wessel et al. 2004 ). 
The THBS4 A387P variant also shows ethnic distribution differences. The THBS4 387P 
allele showed a dramatically lower prevalence in Asian Chinese populations compared 
with Caucasians (3.8% vs 19.6-23.2%) and failed to associate with CAD or MI in the 
studied populations (Zhou et al. 2004). The THBS4 387P allele was associated in men 
(p=0.013) in Japanese population (Yamada et al. 2002). Interestingly, in a more recent 
investigation, the THBS4 variant 387P allele was significantly associated with reduced 
risk, rather than increased risk, for premature MI (OR=0.43, 0.22 to 0.85) in Netherlands 
Caucasians (Boekholdt et al. 2002). McCarthy et al. (2004) analyzed 210 polymorphisms 
in 111 candidate genes in 352 white subjects with familial premature coronary heart 
disease and 418 white controls, and found a strongest association with an A387P variant 
in THBS4 (p = 0.002) (McCarthy et al. 2004). Therefore, the reality of THBS4 A387P in 
MI remains unknown. We believe that the contradictory results may be due to either 
population genetic mixture or the effects of different modifiers for the THBS4 387P 
allele among the different ethnic populations. 
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1.5 Methylenetetrahydrofolate reductase (MTHFR) 
MTHFR is a flavoprotein that catalyzes the reduction of 5,1 0-methylenetetrahydrofolate 
(5,10-CH2-H4 folate) to 5-methyltetrahydrofolate (5-CH3-H4 folate), the major 
circulatory form of folate and methyl donor for homocysteine remethylation, thereby 
regulating the fasting plasma homocysteine level (Figure 2). Hyperhomocysteinemia is 
an established risk factor for CAD and is associated with increased mortality in patients 
with confirmed CAD (Gallagher et al. 1996; Ma et al. 1996; Refsum et al. 1998). Thus, 
total plasma homocysteine is an independent and significant risk factor for CAD. A 
common polymorphism in the MTHFR gene is the underlying cause of moderate 
hyperhomocysteinemia in about half of the cases (Kang et al. 1993; Ma et al. 1996). 
1.5.1 Two common polymorphisms in MTHFR 
In 1995, a common polymorphism was reported, MTHFR 677C>T (rs1801133) (Frosst et 
al. 1995). The change induces thermo lability of the enzyme, and is in the catalytic region. 
In a study with site directed mutagenesis, it was found that enzyme activity of the 
MTHFR carrying the 677T is reduced to 45 %and 677T homozygotes have higher level 
of homocysteine (Weisberg et al. 2001 ). 
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Figure 2. Schematic presentation of folate metabolism in relation to DNA methylation 
and thymidylate synthesis (Kono and Chen 2005). 
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The second common polymorphism, MTHFR 1298A>C (rs1801131) does not induce 
thermolability (van der Put et al. 1998). This polymorphism is as common as the 677C>T 
polymorphism with approximately 10 % homozygotes reported. In a study with site 
directed mutagenesis, enzyme activity of the MTHFR carrying 1298C (having a 
glutamate to alanine substitution) is reduced to 68 %. However, the effects of the 1298C 
and 677T variants are not additive. When this amino acid substitution was introduced into 
an enzyme that already carried the 677T (the alanine to valine substitution) the activity 
was reduced only from 45 % to 41 % (Weisberg et al. 2001 ). These in vitro findings 
support the observation that plasma homocysteine levels are hardly affected in subjects 
carrying the 1298C variant (van der Put et al. 1998; Weisberg et al. 1998; Weisberg et al. 
2001). 
The prevalence of homozygotes for the MTHFR 677T allele in newborns varies between 
different populations: from 2.7 to 32% (Figure 3) (Wilcken et al. 2003). The prevalence 
of homozygotes for 1298C does not differ so much in different populations, 9% in the 
Dutch (van der Put et al. 1998) and Canadian reports (Weisberg et al. 1998), 12.5 %in a 
French study (Chango et al. 2000), and 14.2 % in an Irish population (McCarthy et al. 
2004). 
The MTHFR 677C>T and 1298A>C mutation are in trans configuration (two mutation 
on the different chromosome) (van der Put et al. 1998). Only a few studies have reported 
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that MTHFR 677C> T and 1298A>C mutation occur in cis (co-location of two mutation 
on the same chromosome) (Isotalo et al. 2000). 
1.5.2 MTHFR polymorphisms and MI 
Two variants in the coding region of the MTHFR gene, 677C> T and 1298A>C, have 
been reported to be prevalent in North America, European and Asian populations. The 
677C>T was suggested to moderately reduce the enzyme activity and increase the level 
of plasma homocycteine (Brattstrom and Wilcken 2000). In contrast, 1298A>C alone was 
reported not to significantly affect plasma homocysteine, but may do so only when 
combined with the 677T allele (Weisberg et al. 2001 ). The correlation between risk of 
CAD including MI and the two common variants, 677 C>T and 1298A>C has been 
investigated by a number of studies using a variety of different populations. 
A meta-analysis by Brattstrom et al. (Brattstrom et al. 1998) looked at 23 studies that 
investigated an association between MTHFR genotype and CVD. They concluded that 
the 677T variant is commonly associated with mild hyperhomocysteinemia, while it does 
not increase the risk of CHD (Brattstrom et al. 1998). 
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Figure 3 Prevalence of homozygous TT genotype among newborns (Wilcken et al2003). 
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However, a meta-analysis of the MTHFR 677C> T polymorphism examined 40 
observational studies, involving a total of 11,162 cases and 12,758 controls, found that 
the 677TT genotype was associated with an increased risk of CHD (odds ratio 1.16, 
1.05- 1.28) (Klerk et al. 2002). The CHD risks in European and North American 
populations were determined separately. Europeans with the 677TT genotype had a 
significantly increased risk of CHD (odds ratio 1.14, 1.01- 1.28), while no increase in 
risk was noted for North Americans with this genotype (odds ratio 0.87, 0.73-1.05). 
There was a significant heterogeneity between the results obtained in European 
populations, compared with those in the North American populations, which might 
largely be explained by interaction between the MTHFR 677 C>T polymorphism and 
folate status (Klerk et al. 2002). 
Another meta-analysis examined 72 retrospective studies in which the MTHFR 677C> T 
genotype was analysed in cases and controls, and 20 prospective studies in which total 
plasma homocysteine (tHey) was determined (Wald et al. 2002). In the prospective 
studies, tHey was associated with an increase in risk of ischemic heart disease and stroke. 
Similar results were seen for MTHFR genotypes. A meta-analysis including only 
prospective studies on cardiovascular diseases reported 14 studies with an average 
relative risk of 1.49 (95% CI: 1.31-1. 70) for cardiac events (Bautista et al. 2002). 
Recently, a meta-analysis investigated the association between the MTHFR 677C>T 
polymorphism and CHD (Lewis et al. 2005). No strong evidence was discovered to 
22 
support an association of the MTHFR 677 C>T polymorphism and CHD in Europe, 
North America, or Australia. A PubMed search reveals that only one study has verified 
an association between elevated homocysteine concentration and the 1298C allele (Haviv 
et al 2002), while there are more negative studies of reasonable size (Abu-Amero et al. 
2003). The importance of the 1298A>C polymorphism has also been questioned from a 
biochemical point of view. Compatible with the negative studies, Yamada et al. found 
that purified 1298C-encoded MTHFR showed no difference from wild type either in its 
kinetic or stabilizing properties, regardless of if in trans with 677C or 677T (Yamad et al. 
2001). 
The results of numerous studies (Adams et al. 1996; van Bockxmeer et al. 1997; Morita 
et al. 1997; Schwartz et al. 1997; Friedman et al. 1999; Szczeklik et al. 2001; Kolling et 
al. 2004; Wald et al. 2002; Klerk et al. 2002; Ray et al. 2002; Haviv et al 2002; Abu-
Amero et al. 2003; Lewis et al. 2005) have failed to resolve the controversy in this area. 
Therefore, the relation between the two common variants and the risk of CAD has not 
been established and continues to be the subject of much debate. 
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Chapter 2 
Objectives of the study 
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The development of a first myocardial infarction is associated with a large number of 
contributing factors. Age, male sex, hypertension, smoking, diabetes, body mass index 
and hypercholesterolemia are considered established risk factors. The primary aim of the 
present dissertation was to evaluate whether specific biomarkers could improve the 
prediction of subjects at risk for myocardial infarction. The two SNPs in the MTHFR 
gene and one SNP in the THBS4 gene were suggested to associate with increased risk of 
myocardial infarction with contradictory results. To investigate the possible association 
between these polymorphisms and MI, we study 1032 patients with MI and 1014 normal 
controls in the Newfoundland population. 
The aims of the study conducted for this thesis were: 
1. To test the hypothesis that the THBS4 gene variant is a risk factor for MI. 
2. To confirm the results of our initial study that the 1186 G>C (A387P) variant in the 
THBS4 gene is associated with MI. 
3. To investigate the genetic effects of the 677C>T and 1298A>C in Ml, to analyze the 
distribution of combined genotypes and to estimate haplotype frequencies. 
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Chapter 3 
Materials and Methods 
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3.1 Subjects 
Blood samples were collected from 1032 consecuitive MI patients (640 males and 392 
females) and 1014 normal controls (477 males and 537 females) from the genetically 
isolated Newfoundland population. Patients categorized in the MI group represented 
those presenting to the emergency department within one of the Health Care Corporation 
of St. John's hospitals with symptoms and biochemical evidence suggestive of MI. Only 
patients with cardiac Troponin I values greater than 2.0 J..lg/L (Axsym, Abbott 
Diagnostics) or greater than 0.5 J..lg/L (Access II, Beckman-Coulter Corp.) were used in 
this group (Uettwiller-Geiger et al. 2002). Control subjects were selected from 
consecutive individuals without prior history of MI or thrombosis presenting to the 
emergency department for trauma, accidental injury, or other non-cardiac and non-
thrombotic related events. Discarded blood samples collected for complete blood count 
were used for DNA extraction and analysis. The unmatched controls for age are used, for 
the patients are mostly in older groups, but there were not enough older control. The 
younger control sample may dilute the association power. Subgrouping according gender 
and age will often more precisely estimate the association. Ethics approval for this study 
was granted by the Human Investigations Committee of Memorial University and by the 
Health Care Corporation of St. John's. 
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3.2 Salt extraction-isolation of human genomic DNA from whole blood 
Whole blood was collected from subjects in a lavender vacutainer (EDTA). 5ml of blood 
was then transfered into a 15ml centrifuge tube and 5ml of TKM 1 buffer (1 OmM Tris 
HCl, 10mM KCl, lOmM MgC}z, 2mM EDTA pH7.6)was added. Following this, 1.25 
ml of 10% IGEPAL CA_630 was added, mixed by inversion several times, and 
centrifuged at 2200 rpm for 10 minutes at room temperature. The supernatant was slowly 
poured off to save the nuclear pellet. The pellet was then washed twice in 1 Oml of TKM 1 
buffer, gently resuspended in 0.8ml of TKM2 buffer (lOmM Tris HCl, 10mM KCl, 
10mM MgC}z, 4M NaCl, 2mM EDTA pH7.6 o.) and transfered into a microfuge tube. 
50 J •.t.l of 10% SDS was then added, and the whole suspension was mixed thoroughly by 
pipetting back and forth several times and incubated for 20 to 30 minutes at 50°C. 0.40ml 
of 5M N aCl was added in the tube, vortexed well and centrifuged at 14000rpm for 20 
minutes. The supernatant was then transferred into a 15 ml polypropylene tube. 2.4ml of 
absolute ethanol at room temperature was added and the tubes inverted several times until 
the DNA precipitated. The precipitated DNA strands were removed with a plastic spatula 
or pipette, transferred to a 1.5 ml microcentrifuge tube containing 100-200 J.d TE buffer 
(10 mM Tris-HCI, 0.2 mM Na2EDTA, pH 7.5) and incubated at 65°C for several hours. 
The concentration of DNA was measured by taking A260 and A280 (Miller et al. 1988). 
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3.3 Genotyping of the THBS4 A387P polymorphism 
Genotyping of the THBS-4 1186G>C variant was conducted using Taq Man SNP 
genotyping technology on real-time PCR (ABI Prism® 7000 Sequence Detection System) 
which gives call rate of 99.996%. Primers and probes were designed using the Primer 
Express 2.0 software according to Applied Biosystems' guidelines (Foster city, CA, 
USA). The primers used were: forward: GCACTAGGTCTGCACTGACATTG; and 
reverse: CCGGTTCTGCTTTGATAACAACA. The probes used were: 387A allele: VIC-
AAATGGACCGTGCGTT-TAMRA; 387P allele: FAM-AAATGGAGCGTGCGTT-
T AMRA. PCR reactions were carried out in 96-well optical reaction plates and each 
reaction consisted of l.5f.ll genomic DNA (10 nglf.!L) as template, 7.5f.ll of TaqMan 
Universal PCR Master Mix, 700 nM (each) primer and 200 nM (each) probe in a total 
volume of 15f.ll. After activation of UNG (2 min; 50°C) and AmpliTaq Gold (10 min; 
95°C), 42 cycles of denaturation (15 s; 95°C) and elongation (1 min; 58°C) were used for 
two-step PCR. The fluorescent signals of the two reporter dyes were directly determined 
after PCR. The four distinct clusters were manually categorized as 387GG(VIC), 
387CC(FAM), 387GC (VIC and FAM) and no amplification control (NTC) based on the 
VIC to F AM ratio (Figure 5). 
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Figure 5 Example of distribution ofTHBS4 genotypes when assayed with reahime-PCR. 
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3.4 Genotyping of the MTHFR 677C>T and 1298A>C polymorphisms 
Genotyping of the 677C>T and 1298A>C was conducted usmg Taq Man SNP 
genotyping technology on real-time PCR (ABI Prism® 7000 sequence Detection System). 
The primers and probes for 677C>T and were obtained from the Validated TaqMan SNP 
genotyping kit supplied by Applied Biosystems (ABI; Foster City, CA). The primers for 
1298A>C were: forward: GGAGGAGCTGCTGAAGATGTG; and reverse: 
CCCGAGAGGTAAAGAACAAAGACTT. The probes used were: 1298A allele: VIC-
ACCAGTGAAGAAAGTGT-T AMRA, 1298C allele: F AM-CAGTGAAGCAAGTGT-
T AMRA. PCR reactions were carried out in 96-well optical reaction plates and each 
reaction consisted of 0.3J.ll genomic DNA (100 ng/J.ll) as template, 2.5J.!l of TaqMan 
Universal PCR Master Mix, 700 nM (each) primer and 200 nM (each) probe in a total 
volume of 5J.!l. After activation of UNG (2 min; 50°C) and AmpliTaq Gold (10 min; 
95°C), 40 cycles of denaturation (15 s; 95°C) and elongation (1 min; 60°C) were used for 
two-step PCR. The fluorescent signals of the two reporter dyes were directly determined 
after PCR. The four distinct clusters were manually categorized as 1298A or 677C (VIC), 
1298C or 677T (FAM), 1298NC or 677C/T (VIC and FAM) and no amplification 
control {NTC) based on the VIC to F AM ratio. 
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3.5 Prevalence determination and statistical analysis 
The prevalence of each gene variant was calculated by counting the total earner 
frequency including heterozygotes and homozygotes. The allele frequencies were 
determined by gene counting. Tests of Hardy-Weinberg equilibrium (HWE) were carried 
out for all loci among MI patients and controls separately by the Chi-square test. Pearson 
Chi Square statistical analysis was performed using SPSS v10.0 to test the association 
between genotypes and the prevalence of MI. Odds ratios (OR) were calculated as a 
measure of the relative risk for MI and were given with 95% Cis. Genetic power was 
calculated using the method for case-control studies of discrete traits posted on the web 
page of the Psychiatric and Neurodevelopmental Genetics Unit (PNGU) at Harvard 
Medical School (http://pngu.mgh.harvard.edu/-purcell/cgi-binlcc2.cgi). 
3.6 Haplotype frequency estimate 
The haplotype frequencies were estimated via the method of maximum likelihood from 
genotype data through the use of the expectation-maximization (EM) algorithm under the 
assumption of HWE (Fallin and Schork 2000). Haplotype frequencies for various marker 
combinations were estimated for MI patients and controls separately. Linkage 
disequilibrium between the 677C>T and 1298A>C variants was calculated as D', which 
ranges from 0 (no linkage disequilibrium) to 1 or -1 (complete linkage disequilibrium) 
(Lewontin 1988). 
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A recently identified novel missense variant of THBS4, A389P (29926 G>C) was 
correlated with premature myocardial infarction (MI) by an exploratory genetic 
association study on 184 MI patients from the American population (Topol et al. 2001). 
In this study, the THBS4 387P allele showed the strongest association, with an adjusted 
odds ratio for MI of 1.89 (P=0.002 adjusted for covariates) for individuals carrying the 
387P allele. This was replicated by the same group using a larger number of patients 
patients (Wessel et al. 2004). An in vitro functional study of the THBS4 A387P 
substitution provided further evidence in support of a proatherogenic effect. The THBS4 
A387P substitution was shown to have a gain of function effect leading to suppression of 
endothelial cell adhesion and proliferation (Stenina et al. 2003). The THBS4 A387P 
variant also shows ethnic distribution differences. The THBS4 387P allele showed a 
dramatically lower prevalence in Asian Chinese populations compared with whites (3.8% 
versus 19.6 to 23.2%) and failed to associate with coronary artery disease (CAD) or MI in 
the studied populations (Zhou et al. 2004). Interestingly, in a more recent investigation, 
the THBS4 variant 387P allele was significantly associated with reduced risk, rather than 
increased risk, for premature MI (OR=0.43, 0.22 to 0.85) in Netherlands whites 
(Boekholdt et al. 2002). Therefore, the true effect of THBS4 A387P in MI remains 
unknown. We believe that the contradictory results may be caused by either population 
genetic mixture or the effects of different modifiers for the THBS4387P allele among the 
different ethnic populations. 
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We examined the THBS4 A387P variant as part of our study to explore potential gene 
variants as risk factors for MI and the effect of interaction between different variants on 
MI. So far 11 different variants have been analyzed, and some have been published 
(Zheng et al. 2002; Butt et al. 2003; Xie et al. 2003). To test the hypothesis that the 
THBS4 variant constitutes increased risk for MI we carried out a case control study by 
genotyping the THBS4 A387P in a large number of patients with MI from the genetically 
isolated Newfoundland population. This approach reduces the effects of genetic 
admixture in the studied subjects, a common challenge facing case control studies. The 
population of the island of Newfoundland consists mainly of descendants of English and 
Irish settlers who arrived in the 17th and 18th Centuries (Bear et al. 1987; Martin et al. 
2000). The geographical and social isolation of this island has ensured very little inward 
migration for several hundred years and thus has led to a small population (530 000 
individuals; Statistics Canada 2001) with a relatively homogenous genetic background 
ideal for the study of complex multifactorial disease such as MI. 
Blood samples were collected from 500 consecutive MI patients (306 males and 194 
females) and 500 normal controls (214 males and 286 females) of the genetically isolated 
Newfoundland population. Patients categorized in the MI group represented those with 
symptoms and biochemical evidence suggestive of MI (Troponin I values >2.0 f.! giL or 
>0.5 f.!g/L). Control subjects were selected from consecutive individuals without prior 
history of MI or thrombosis presenting to the emergency department for trauma, 
accidental injury, or other noncardiac and nonthrombotic related events. Ethics approval 
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for this study was granted by the Human Investigations Committee of Memorial 
University and by the Health Care Corporation of St. John's. 
Genotyping of the THBS4 A387P polymorphism was conducted by using Taq Man SNP 
genotyping technology on real-time PCR. The primers used were: forward, 
GCACTAGGTCTGCACTGACATTG; and reverse, 
CCGGTTCTGCTTTGATAACAACA. The probes used were: 387A allele, 
AAA TGGACCGTGCGTT, which was labeled at the 5' end with VIC; 387P allele, 
AAA TGGAGCGTGCGTT, which was labeled at the 5'end with F AM. Both probes also 
had a quencer dye T AMRA at 3 '. 
Pearson .t2 statistical analysis was performed using SPSS vlO.O to test the association 
between genotypes and the prevalence of MI. Odds ratios (OR) were calculated as a 
measure of the relative risk for MI and were given with 95% Cis. 
Our study showed that both patients and controls were in Hardy-Weinberg equilibrium 
for the A387P polymorphism. The gene frequency of THBS4 A387P in the 
Newfoundland population was 23.1 %, similar to other white populations. Slightly 
increased carrier frequency, allele frequency, and homozygous frequency of the 387P 
allele were observed in patients with MI compared with controls (43.6% versus 41.8%, 
24.9% versus 23.1%, and 6.2% versus 4.4%, respectively), but the differences did not 
reach statistical significance (Table 2). 
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The distribution of the THBS4 A387P variant was further analyzed by subgrouping 
patients and controls according to age and sex (Table 2). MI patients were divided into 
those with an early age of onset (:$50 years) and those with a later age of onset (>50 
years). The control population was also divided into the 2 corresponding age groups. 
The 387P allele showed a tendency toward higher prevalence in female patients with MI 
compared with the controls of same sex and gave an OR of 1.34 (0.930, 1.944), but the 
difference was not statistically significant (P=0.132; Table2). However, the prevalence of 
homozygotes for the 387P allele was significant higher in female patients compared with 
the female controls, giving an odds ratio of2.96 (1.29, 6.78; P=0.008). In contrast, there 
was a tendency toward reduced prevalence of the 387P allele and homozygosity in male 
patients with MI compared with the male controls (41.8% versus 45.3% and 4.6% versus 
6.1% ). These differences were not statistically significant. 
Genetic predisposition in multifactorial disease, such as MI, results from the coeffect of 
multiple genes, gene-gene, and/or gene-environment interactions. These collectively 
produce an additive or synergistic effect which affects risk for disease. Individual genetic 
changes may produce small or insufficient effects to impart significant pathogenic risk. 
Therefore, it is not surprising to see that most of the genetic variants associated with MI 
are characterized as polymorphisms rather than mutations. Gene-gene interaction as a 
significant factor in genetic predisposition for MI has been clearly demonstrated in our 
previous studies (Butt et al. 2003; Xie et al. 2003). 
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Table 2 Distribution of Heterozygote and Homozygote for THBS4 387P Genotypes 
Among MI Patients With Different Onset Ages, Genders, and Compared With Age and 
Gender Matched NC 
MI NC OR(95% CI) p 
THBS4A387P 
CC+GC 218/500 (43.6%) 209/500 (41.8%) 1.08 (0.84, 1.38) 0.565 
cc 311500 (6.2%) 22/500 (4.4%) 1.44 (0.82,2.52) 0.204 
Males 
CC+GC 128/306 (41.8%) 97/214 (45.3%) 0.87(0.61,1.23) 0.428 
cc 14/306 (4.6%) 13/214 (6.1 %) 0.74(0.34,1.61) 0.448 
Females 
CC+GC 90/194 (46.4%) 112/286 (39.2%) 1.34 (0.93,1.94) 0.132 
cc 17/194 (8.8%) 9/286 (3.1%) 2.96 (1.29,6.78) 0.008 
Age:S 50Y 
CC+GC 25/54 (46.3%) 154/378 (40.7%) 1.25 (0.71,2.22) 0.463 
cc 3/54 (5.5%) 18/378 (4.8%) 1.18 (0.34,4.14) 0.736 
Age> 50Y 
CC+GC 193/446 (43.3%) 55/122 (45.1 %) 0.93 (0.62,1.39) 0.758 
cc 28/446 (6.2%) 4/122 (3.3%) 2.04 (0. 70,5.94) 0.181 
CC is 387PP and GC is 387AP. 
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In our present study, the 387P allele showed a tendency toward increased prevalence in 
the MI patients group compared with the controls. The carrier frequency of the 387P 
allele (GC+CC) was only slightly higher in patients with MI compared with the controls 
(43.6% versus 41.8%; OR 1.08). However, such increases become remarkable when 
comparing the prevalence of homozygosity for the 387P allele between patients and 
controls (6.2% versus 4.4%; OR 1.436). Further analysis of the 387P allele in subjects 
subgrouped according to sex showed that the higher prevalence of 387P alleles in MI 
patients only occurs in females. Female MI patients compared with control females gave 
odds ratios of 1.34 (P=0.132) and 2.96(P=0.008), respectively, when compared for 
prevalence of carriers (genotype of CC+GC) and homozygotes (genotype of CC). This 
indicates that the 387P allele may be a weak and dosage sensitive risk factor for MI. 
Other female-specific factors, genetic or otherwise, may have modifying effects on the 
relationship of 387P with MI risk. 
Based on our investigation it is not clear whether the 387P allele has any effect on MI risk 
for male patients. We noticed a trend of reduced prevalence for 387P in carriers and 
homozygous males in the MI group compared with male controls (41.8% versus 45.3% 
and 4.6% versus 6.1 %). However, the difference did not reach statistical significance. 
Further study on increased sample size will be useful. 
Our results showed an increased prevalence of the 387P allele in patients with MI. This is 
in contrast with the results from the Netherlands study, in which the 387P alleles were 
associated with a reduced risk for MI (Boekholdt et al. 2002). Several differences are 
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worth noting, however. The Netherlands study examined patients with early onset MI, a 
situation where one would expect strong predisposing factors to be most relevant. Our 
study examines a much older MI population where the etiology for MI may be 
significantly different. Secondly, the Netherlands study population had a high proportion 
of males (~80%) compared with our study (~50%). 
Finally, we conclude that THBS4 A387P polymorphism is associated with MI in females, 
especially in female homozygosity condition. 
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Abstract 
Background: Case-control studies have successfully identified many genetic associations 
for complex diseases, but suffer from lack of reproducibility in the same population. 
Demonstrating weak genetic effects requires large sample sizes to minimize statistical 
bias. Based on a study examining 500 myocardial infarction (MI) patients and 500 
controls from the genetically isolated Newfoundland population, we previously reported 
that thrombospondin-4 1186G>C variant associates with MI in females. To validate this 
sex-dependent association with the THBS-4 variant, we analyzed an additional 532 
patients and 514 controls from the same population, and the combined cohort consisting 
of 1,032 patients and 1,014 controls. 
Methods: Genotyping of THBS-4 1186G>C was conducted using Taq Man SNP 
genotyping technology on real-time PCR. 
Results: The genotype distributions ofTHBS-4 1186G>C in the validation and combined 
cohorts were similar with those in our initial study which supports genetic homogeneity 
in the studied population. The association of the CC genotype with MI in females (OR= 
2.96; P = 0.008), reported in our initial cohort, failed to achieve statistical significance in 
our validation cohort (OR= 1.53; P= 0.307), but was confirmed in the combined cohort 
(OR = 2.14; P=0.009). In contrast to the results from the initial cohort was a significant 
association of the CC genotype with later onset MI in the validation (OR = 2.37; P = 
0.029) and combined cohorts (OR: 2.22, P = 0.011). Moreover, the larger studied 
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population gave statistical power to associate the CC genotype with risk of MI in the total 
patient population (OR=1.58, P=0.023). 
Conclusion: Homozygosity for the THBS-4 1186C variant is a weak risk factor for MI 
especially in older females. 
Keywords: 
Myocardial infarction, thrombospondin-4 1186 G>C, association study 
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Introduction 
Case-control association analysis is a commonly used study design in the field of 
complex trait genetics. The genetic associations, however, are not consistently 
reproducible due to inadequate sample size, population stratification, complexity of 
mechanisms, multiplicity of causative genes, confounding gene-environment interactions, 
and complex dependency of the associations (Ioannidis et al. 2001, Hirschhorn and 
Altshuler 2002, Colhoun et al. 2003, Hegele 2002). Therefore, cautious replication of 
studies is usually necessary (Joannidis et al. 2001 ). Thrombospondins-4 (THBS-4) is one 
of five members of the THBS family of multidomain extracellular matrix proteins 
(named THBS-1 to 5) which all have been detected in vascular tissue (Wight et al. 1985, 
Lawler et al. 1993, Stenina et al. 2003). Members of the THBS are involved in a wide 
range of processes involving the vessel wall, including smooth muscle cell proliferation 
(Majack et al. 1986) and migration (Taraboletti et al. 1990) and associated with various 
extracellular matrix proteins (Narouz-Ott et al. 2000). THBS-4 appears to be more 
specific to cardiac and skeletal muscle (Lawler et al. 1993). A variant in the coding 
region ofTHBS-4 gene, 1186G>C (A387P) (rs1866389) is predicted to affect folding and 
secretion of the protein and disruption of the calcium binding site (Bomstein 1992, 
Geowjon and Deleage 1994), and may affect the cellular dynamics of the vessel wall 
(Stenina et al. 2003). The inhibitory effects of the THBS-4 1186G>C on endothelial cell 
(EC) repair functions, coupled with its stimulatory effects on smooth muscle cell (SMC), 
may predispose the vasculature to the initiation and development of atherosclerotic 
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lesions (Stenina et al. 2003). We had previously reported a sex dependent association of 
the THBS-4 1186G>C variant with myocardial infarction (MI) in an association study 
using 500 MI patients and 500 controls from the genetically isolated Newfoundland 
population (Cui et al. 2004). To confirm the results of our initial study, we carried out a 
validation study for THBS-4 1186G>C by examining an independent cohort from the 
same population and combining it with our previous results to give a final study 
population consisting of 1,034 patients and 1,014 controls. 
Material and Methods 
Subjects: 
Blood samples were collected from 1,032 consecutive MI patients (640 males and 392 
females) and 1,014 normal controls (477 males and 537 females) of the genetically 
isolated Newfoundland population. These samples included the 500 MI patients and 500 
healthy controls used in our initial case control study. Patients categorized in the MI 
group represented those presenting to the emergency department or within one of the 
Health Care Corporation of St. John's hospitals with symptoms and biochemical evidence 
suggestive of MI. Only patients with cardiac Troponin I values greater than 2.0 Jlg/L 
(Axsym, Abbott Diagnostics) or greater than 0.5 Jlg/L (Access II, Beckman-Coulter 
Corp.) were used in this group. These levels of cardiac Troponin I are consistent with a 
degree of myocardial damage that constitutes MI according to World Health 
Organization criteria. Control subjects were selected from consecutive individuals 
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without prior history of ¥I or thrombosis presenting to the emergency department for 
trauma, accidental injury, or other non-cardiac and non-thrombotic related events. 
Discarded blood samples collected for complete blood count were used for DNA 
extraction and analysis. Ethics approval for this study was granted by the Human 
Investigations Committee of Memorial University and by the Health Care Corporation of 
St. John's. 
Newfoundland population: 
The island portion of the Canadian province of Newfoundland and Labrador is located in 
the Atlantic Ocean. The population of the island of Newfoundland mainly originated 
from the descendants of small number of Irish and southwest English settlers who arrived 
in the 17th and 18th centuries (Bear et al. 1987). The geographical and social isolation of 
this island has ensured very little inward migration for several hundred years (Martin et 
al. 2000) and thus has lead to a small population (530 000 individuals; Statistics Canada 
2001) with a relatively homogenous genetic background ideal for the study of complex 
multifactorial disease such as MI. 
Genotyping of the THBS-4 A387P polymorphism: 
Genomic DNA was isolated from peripheral blood using standard salt precipitation 
methods. Genotyping of the THBS-4 1186G>C variant was conducted using Taq Man 
SNP genotyping technology on real-time PCR (ABI Prism® 7000 Sequence Detection 
System) which gives call rate of 99.996%. Primers and probes were designed using 
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Primer Express 2.0 software according to Applied Biosystems' guidelines (Foster city, 
CA, USA). The primers were GCACTAGGTCTGCACTGACATTG and 
CCGGTTCTGCTTTGATAACAACA. The probe for the 11860 allele is VIC-
AAATGGACCGTGCGTT-TAMRA, and the probe for the 1186C allele is FAM-
AAATGGAGCGTGCGTT-TAMRA. PCR reactions were carried out in 96-well optical 
reaction plates and each reaction consisted of 0.3J.ll genomic DNA (10 ng!J..LL) as 
template, 2.5J.ll of TaqMan Universal PCR Master Mix, 700 nM (each) primer and 200 
nM (each) probe in a total volume of 5J.ll. After activation ofuracil-N-glycolase (UNO) 
(2 min; 50°C) and AmpliTaq Gold (10 min; 95°C), 42 cycles of denaturation (15 s; 95°C) 
and elongation (1 min; 58°C) were used for two-step PCR. The fluorescent signals of the 
two reporter dyes were directly determined after PCR. The four distinct clusters were 
manually categorized as 118600 (VIC), 1186CC (F AM), 1186GC (VIC and F AM) and 
no amplification control (NTC) based on the VIC to F AM ratio. 
Prevalence determination and statistical analysis: 
The prevalence of each gene variant was calculated by counting the total carrier 
frequency including heterozygotes (GC) and homozygotes (CC). The allele frequencies 
were determined by gene counting. To determine whether the polymorphisms were in 
Hardy-Weinberg equilibrium, the actual and predicted genotype counts for controls were 
compared using Chi square analysis with two degrees of freedom. Pearson Chi Square 
statistical analyses was performed to test the association between genotypes and the 
prevalence of MI. Odds ratios (OR) were calculated as a measure of the relative risk for 
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MI and were given with 95% Cis. A two-tailed P<0.05 was considered statistically 
significant. All analyses were performed using SPSS for Windows (Version 11.0, SPSS, 
Chicago, Illinois, USA). Genetic power was calculated using the method for case-control 
studies of discrete traits posted on the web page of the Psychiatric and 
Neurodevelopmental Genetics Unit (PNGU) at Harvard Medical School 
(http://pngu.mgh.harvard.edu/-purcell/cgi-binlcc2.cgi). 
Results 
The genotype distributions ofTHBS-4 1186G>C (A387P) in both the MI patient and the 
control populations are given in table 3. For comparison, the previously published data 
form table2 our initial study were also included in the table 3. In all cohorts the genotype 
distributions of THBS-4 1186G>C in both the MI patients and the healthy control 
population were all in Hardy-Weinberg equilibrium. The calculated genetic power to 
detect an overall association was 45% in the initial cohort and 74% in the combined 
cohort. The results for the validation cohort are similar to that of the initial cohort. When 
data from both were combined the CC, but not GC, genotype showed a significantly 
increased frequency in MI patients (6.40%) compared with the controls (4.14%) 
(OR=l.581, 95% CI 1.063-2.352, P=0.023). However, the total carrier frequency 
(GC+CC) did not show distribution disequilibrium between the MI patients (41.38%) and 
the controls (40.93%) (OR=l.019, 95% CI 0.854-1.215, P=0.837). 
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Table 3. Distributions of genotypes of THBS4 1186G>C (A3 87P) in MI patient and NC 
populations. 
Genotype MI (%) NC(%) OR ( 95%CI) P value 
Initial 
GC 187/500 (37.4) 187/500 (37.4) 1.00(0.77,1.29) 1.000 
cohort* 
cc 311500(6.2) 22/500 (4.4) 1.44(0.82,2.52) 0.204 
GC+CC 218/500(43.6) 209/500(41.8) 1.08(0.84,1.38) 0.565 
Validation 
GC 174/532 (32.7) 186/514 (36.2) 0.86(0.66,1.11) 0.236 
cohort 
cc 35/532 (6.6) 20/514 (4.0) 1.74(0.99,3.06) 0.052 
GC+CC 209/532(39.3) 206/514(40.1) 0.97(0.76,1.24) 0.793 
Combined 
GC 361/1032 (35.0) 373/1014 (36.8) 0.93(0.77,1.11) 0.395 
cohort 
cc 6611032 (6.4) 42/1014 (4.1) 1.58(1.06,2.35) 0.023 
GC+CC 427/1032(41.4) 415/1014(40.9) 1.02(0.85,1.22) 0.837 
*Cui et al. Arterioscler Thromb Vase Bioi. 2004; 24(11):e183-4 
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Table 4. Genotype Distribution ofTHBS4 1186G>C (A387P) in the onset age and gender 
based MI patients and NC subpopulations. 
Genotype MI(%) NC(%) OR(95%CI) p 
value 
Initial cohort* 
Onset age:::; CC+GC 25/54 (46.3) 154/378 (40.7) 1.25 (0.70,2.22) 0.463 
50 
cc 3/54 (5.6) 18/378 (4.8) 1.18 (0.34,4.14) 0.736 
Onset age GC+CC 193/446(43.3) 55/122(45.1) 0.93 (0.62,1.40) 0.758 
>50 
cc 28/446 (6.3) 4/122 (3.3) 1.93 (0.62,5.75) 0.181 
Male GC+CC 128/306 (41.8) 97/214 (45.3) 0.87 (0.61,1.23) 0.428 
cc 14/306 ( 4.6) 13 /214 (6.1) 0.74 (0.34,1.61) 0.448 
Female GC+CC 90/194 (46.4) 112/286 (39.2) 1.34 (0.93,1.94) 0.132 
cc 17/194 (8.8) 9/286 (3.2) 2.96 (1.29,6.78) 0.008 
Validation cohort 
Onset age:::; CC+GC 30/85 (35.3) 94/233 ( 40.3) 0.81 (0.48,1.35) 0.414 
50 
cc 6/85 (7.1) 12/233 (5.2) 1.40 (0.51, 3.85) 0.515 
Onset age GC+CC 179/447 (40.1) 112/281 (39.9) 1.01 (0.73,0.87) 0.960 
>50 
cc 29/447 (6.5) 8/281 (2.9) 2.37 (1.07,5.26) 0.029 
Male GC+CC 129/334 (38.6) 106/263 (40.3) 0.93 (0.67,1.30) 0.676 
cc 22/334 (6.6) 9/263 (3.4) 1.99 (0.90,4.40) 0.084 
Female GC+CC 80/198 (40.4) 100/251 (39.8) 1.02 (0.70,1.50) 0.904 
cc 13/198 (6.6) 111251 (4.4) 1.53 (0.67,3.50) 0.307 
Combined cohort 
Onset age:::; GC+CC 55/139(39 .6) 248/611(40.6) 0.96 (0.66, 1.40) 0.825 
50 
cc 9/139 (6.5) 30/611 (4.9) 1.34 (0.62,2.89) 0.453 
Onset age GC+CC 372/893(41.7) 167/403(41.4) 1.01 (0.80,1.28) 0.941 
>50 
cc 57/ 893 (6.4) 12/ 403 (3.0) 2.22 (1.18,4.19) 0.011 
male GC+CC 257 /640( 40.2) 203/477(42.6) 0.91 (0.81,1.15) 0.420 
cc 36 I 640 (5.6) 22 I 477 (4.6) 1.23 (0.72,2.12) 0.450 
Female GC+CC 170/392(43.4) 212/537(39.5) 1.17 (0.90,1.53) 0.234 
cc 30 I 392 (7. 7) 20 I 537 (3.7) 2.14 (1.20,3.83) 0.009 
*Cui et al. Arterioscler Thromb Vase Bioi. 2004; 24(11):e183-4 
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The THBS-4 1186G>C was further analyzed by sub-grouping patients and controls 
according to age and sex (Table 4). The corresponding data from our initial study were 
also included in table 4 for comparison. To determine the relationship with age, the 
THBS-4 1186G>C was analyzed in the MI patients who were divided into those with an 
early age of onset (~ 50 years) and those with a later age of onset (>50 years). The 
control population was also divided into the two corresponding age groups. There was no 
significant distribution disequilibrium for the genotypes CC + CG and CC between the 
early onset MI patients and the age matched controls in either the validation or the 
combined cohort. In the later onset MI patients, the prevalence of CC genotype was 
significantly increased compared with age matched controls in both of the validation 
cohort (OR= 2.37, P=0.029) and combined cohort (OR= 2.22, P=O.Oll). This effect was 
not seen in the initial cohort, although the trend was present. Examination of the effect of 
sex showed that the prevalence of the CC genotype remained significantly higher in 
female patients compared with the sex matched controls (OR=2.14, P = 0.009) in the 
combined cohort. This confirms the observation made in our initial study. Only the trend 
was evident in the validation cohort which did not achieve statistical significance. 
Discussion 
Being a multifactorial disorder, the genetic components in MI may be a combined effect 
of a number of genes with each playing only a small role. Case control studies using 
genetically isolated populations are of advantage due to a relatively homogenous genetic 
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background. However, the effect of a weak genetic risk factor can easily be influenced by 
any of a number of different genetic and environmental factors which may vary among 
individuals in the same population. Cases-control studies for investigating weak risk 
factors, therefore, require the study of large populations in order to show an effect. The 
THBS-4 1186G>C was suggested to impart a weak sex dependent predisposition for MI 
in our initial study based on the fact that only the CC genotype showed significant risk 
for MI in females (Cui et al. 2004). In order to eliminate a possible statistical error, due a 
small study population, we analyzed an addition 532 patients and 514 controls from the 
same population and combined this with results from the original 500 patients and 500 
controls in the initial study. 
The genotype distribution ofTHBS-4 1186G>C in MI patients and controls are similar in 
both our initial and present study (table 3 and 4). This supports a homogenous genetic 
background of the Newfoundland population. The sex dependent association of the CC 
genotype with MI is further confirmed in the combined cohort of this study (OR: 2.14, 
P=0.009) although only the trend was present in the validation cohort. This is at least 
partially due to the lower odds ratio indicated in the validation cohort and insufficient 
power using a small sample size. The equilibrium distribution of the CC genotype was 
detected in the later onset MI patients compared with the age matched controls in the 
validation cohort (OR: 2.37, P = 0.029) and combined cohort (OR: 2.22, P = 0.011) but 
not in the initial cohort, although a trend of increasing prevalence was present in the 
initial cohort (OR: 1.93, P = 0.18). Furthermore, similar CC genotype prevalences were 
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found in the initial, the validation, and combined cohorts, it is only in the combined 
cohort that the difference in prevalence in MI patients compared with controls becomes 
statistically significant (OR: 1.58, P= 0.023) for the unsubgrouped populations. The 
greater statistical power gained by using the larger combined populations is the main 
explanation for this effect. In the present study, the genetic power was increased from 
45% to 74% when the samples size increased from 500 to 1014. The findings were 
inconsistent in achieving statistical significance when the smaller cohorts were examined. 
This illustrates the importance of a large scale case control study for investigating weak 
causative genetic predisposition. 
In summary, we validated our previous case control study for the THBS-4 1186G>C 
variant using a combined cohort consisting of subjects from the initial study and an 
additional 532 MI patients and 514 healthy controls from the same genetically isolated 
Newfoundland population. The combined cohort consisted of 1,032 patients with MI and 
1,014 healthy controls. The genotype distributions of THBS-4 1186 G>C in the 
expanded population was similar with those obtained in our initial study and supports 
genetic homogeneity within the Newfoundland population used. The sex-dependent 
association of the CC genotype with MI reported in our initial study was confirmed in 
this study. This suggests that some female-specific factors, genetic or otherwise, may 
have modifying effects on the relationship of CC genotype with MI risk. Moreover, the 
larger population studied here gave the necessary statistical power to establish an 
association of the CC genotype with the entire MI population and more specifically later 
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onset MI patients. Based on these results, we conclude that the THBS-4 1186C variant is 
a weak risk factor for MI when individuals are of homozygous status, and such 
predisposition may be more important for older females. 
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Abstract 
Studies exammmg the role of methylenetetrahydrofolate reductase (MTHFR) gene 
variants, 677C>T and 1298A>C, in myocardial infarction (MI) have yielded discordant 
results. This is possibly due to interaction of complex genetic and environmental 
modifiers which vary among populations. To reduce such influences, a large case-control 
study using a genetic homogenous population would be of great advantage. We, 
therefore, carried out a large cohort for studying these two variants in 1,032 MI patients 
and 1,014 controls from the genetically isolated Newfoundland population. Genotyping 
results showed a significantly increased prevalence of 1298C (OR=1.369, P<0.001), but 
only a trend toward decreased prevalence of 677T (OR=0.847, P=0.062) in patients 
compared with the controls. Combined genotype analysis showed distribution 
disequilibrium of 677CT+TT/1298AA (OR=0.700, P<0.001) and 677CC/1298AC+CC 
(OR=1.205, P=0.048) in patients. The combined genotype 677CT+TT/1298AC+CC 
presented only a trend toward increased prevalence in patients (OR=1.221, P=0.056). 
Analysis of estimated haplotype-frequencies demonstrated linkage disequilibrium for the 
667T-1298C (OR=3.206, P<O.OOI), but not for 677C-1298C (OR=1.106, P = 0.133) in 
patients. A further age based sub-population study showed the distribution 
disequilibrium of 1298C (AC+CC) with late onset MI patients (OR=l.513, P=0.001). 
These results suggest: 1) the 677T is a weak protective factor against MI but its effect is 
silenced when it is in cis with 1298C; 2) the 1298C is a risk factor for later onset MI and 
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its effect is reduced by an in trans 677T. These effects may be responsible for the lack of 
agreement among previous association studies examining MTHFR gene variants in MI. 
Keywords 
Newfoundland population, MTHFR gene variants, Myocardial infarction, Association, 
Haplotype 
57 
Introduction 
Methylenetetrahydrofolate reductase (MTHFR) is essential for homocysteine metabolism 
(Frosst et al. 1995). The two MTHFR common variants, 677C>T and 1298A>C 
especially the 677C>T have been extensively studied as risk factors for CAD including 
MI mainly due to its association with increased levels of homocysteine which are 
commonly observed in CAD patients (Danesh and Lewington 1998). Outcomes from a 
large number of previous association studies between 677T and CAD and MI were 
controversial though several meta analysis were included (Brattstrom et al. 1998; Wald 
et al. 2002; Klerk et al. 2002; Lewis et al. 2005). In contrast, the correlation between 
CAD and the 1298C allele has been less studied and only a few studies with inconsistent 
results were reported (Kolling et al. 2004; Strauss et al. 2005). Given that increases in 
homocysteine caused by MTHFR 677C>T and 1298A>C are relatively small, the effects 
of 677T and 1298C on CAD are expected to be weak. High prevalence of the two 
variants in different ethnic populations and discordant results in previous association 
studies for CAD suggest that the potential effects of both alleles in CAD may be 
universal but influenced by multiple yet unknown genetic and/or environmental factors 
which vary among different ethnic populations. To assess the suspected weak genetic 
effects from the 677T and 1298C, large study populations are required to provide 
sufficient statistical power to detect possible allele-allele interactions. Use of genetically 
isolated populations help to reduce the effects of other genetic modifiers and/or 
environmental conditions. For this purpose, we performed a case-control study in 1032 
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MI patients and 1014 healthy controls from a genetically isolated Newfoundland 
population. Our study not only focuses on determining the different distributions of each 
individual gene variant in the studied population, but also on investigating a possible 
intragenic allelic interaction between 677T and 1298C alleles through combined 
genotype analysis and haplotype calculation. 
Material and Methods 
Subjects: 
Blood samples were collected from 1032 consecuitive MI patients (640 males and 392 
females) and 1014 normal controls (477 males and 537 females) of the genetically 
isolated Newfoundland population. Patients categorized in the MI group represented 
those presenting to the emergency department or within one of the Health Care 
Corporation of St. John's hospitals with symptoms and biochemical evidence suggestive 
of MI. Only patients with cardiac Troponin I values greater than 2.0 Jlg/L (Axsym, 
Abbott Diagnostics) or greater than 0.5 Jlg/L (Access II, Beckman-Coulter Corp.) were 
used in this group. Control subjects were selected from consecutive individuals without 
prior history of MI or thrombosis presenting to the emergency department for trauma, 
accidental injury, or other non-cardiac and non-thrombotic related events. Discarded 
blood samples collected for complete blood count were used for DNA extraction and 
analysis. Ethics approval for this study was granted by the Human Investigations 
Committee of Memorial University and by the Health Care Corporation of St. John's. 
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Newfoundland population 
The island portion of the Canadian province of Newfoundland and Labrador is located in 
the Atlantic Ocean. The population of the island of Newfoundland mainly originated 
from the descendants of small number of Irish and southwest English settlers who arrived 
in the 17th and 18th centuries (Bear et al. 1987). The geographical and social isolation of 
this island has ensured very little inward migration for several hundred years (Martin et 
al. 2000) and thus has lead to a small population (530 000 individuals; Statistics Canada 
2001) with a relatively homogenous genetic background. The living habit and diet are 
similar in the total population. This makes this population ideal for study of complex 
multifactorial disease such as MI. 
Genotyping of the MTHFR 677C>T and 1298A>C: 
Genomic DNA was isolated from peripheral blood using standard salt precipitation 
methods (Miller et al. 1988). Genotyping of the 677C>T and 1298A>C were conducted 
by using TaqMan SNP genotyping technology on real~time PCR (ABI Prism® 7000 
sequence Detection System). The primers and probes for 677C>T and were obtained 
from the Validated TaqMan SNP genotyping kit supplied by Applied Biosystems (ABI; 
Foster City, CA). The primers for 1298A>C were: forward: 
GGAGGAGCTGCTGAAGATGTG; and reverse: 
CCCGAGAGGTAAAGAACAAAGACTT. The probes used were: 1298A allele: 
ACCAGTGAAGAAAGTGT, which was labelled at the 5' end with VIC; 1298C allele: 
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CAGTGAAGCAAGTGT, which was labelled at the 5'end with FAM. Both probes also 
had a quencer dye T AMRA at the 3' end. PCR reactions were carried out in 96-well 
optical reaction plates and each reaction consisted of0.3J..1l genomic DNA (100 ng/J..tl) as 
template, 2.5J.tl of TaqMan Universal PCR Master Mix, 700 nM (each) primer and 200 
nM (each) probe in a total volume of 5J.tl. After activation of UNG (2 min; 50°C) and 
AmpliTaq Gold (1 0 min; 95°C), 40 cycles of denaturation (15 s; 95°C) and elongation (1 
min; 60°C) were used for two-step PCR. The fluorescent signals of the two reporter dyes 
were directly determined after PCR. The four distinct clusters were manually categorized 
as 1298A or 677C (VIC), 1298C or 677T (FAM), 1298A/C or 677C/T (VIC and FAM) 
and no amplification control (NT C) based on the VIC to F AM ratio. 
Prevalence determination and statistical analysis: 
The prevalence of each gene variant was calculated by counting the total earner 
frequency including heterozygotes and homozygotes. The allele frequencies were 
determined by gene counting. Tests of Hardy-Weinberg equilibrium (HWE) were carried 
out for all loci among MI patients and controls separately by the Chi-square test. Pearson 
Chi Square statistical analysis was performed using SPSS vlO.O to test the association 
between genotypes and the prevalence of MI. Odds ratios (OR) were calculated as a 
measure of the relative risk for MI and were given with 95% Cis. The estimated 
haplotype frequencies from the unphased diploid genotype was calculated via the method 
of maximum likelihood from genotype data through the use of the expectation-
maximization (EM) algorithm under the assumption of HWE (Fallin and Schork 2000). 
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Haplotype frequencies for various marker combinations were estimated for MI patients 
and controls separately. Linkage disequilibrium between the 677C>T and 1298A>C 
variants was calculated as D', which ranges from 0 (no linkage disequilibrium) to I or -1 
(complete linkage disequilibrium) (Lewontin 1988). 
Results 
Genotyping MTHFR 677C>T and MTHFR 1298A>C 
The genotype distributions of both 677C>T (CC, CT and TI) and 1298A>C (AA, AC 
and TT) in the controls were all in the Hardy-Weinberg equilibrium. A high degree of 
linkage disequilibrium was observed between the C677T and A1298C polymmphisms 
(D' = -0.714 for case, D'= -0.903 for control). The negative sign of the D' indicates that 
the 677C-1298C (or 677T-1298A) alleles were linked. The distributions of individual 
and combined genotypes of the 677C>T and 1298A>C in the MI patients and the 
controls are given in Table 5. The 677T allele (CT and TT) showed a trend toward a 
lower prevalence in the MI patients compared with the controls (53.2% vs. 57.30%), 
(OR=0.874, 95% CI 0.711-1.009, P=0.062). This trend was also reflected by a lower 
odds ratio among patients with TT genotype compared with those with only CT genotype 
(OR: 0.818 vs. 0.917, P value: 0.157 vs. 0.328). In contrast, the 1298C allele (AC and 
CC) presented a significantly increased prevalence in the MI patients (60.37%) compared 
with the controls (52.66%) (OR=l.369, 95% CI 1.149-1.632, P <0.001). 
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Combined genotype analysis and calculation of estimated haplotype frequency 
The distributions of combined genotypes between 677C/T and 1298NC in MI patient 
and control groups are depicted in Table 5. As expected, the frequency of double 
homozygosity for wild type alleles (677AN1298CC) were found equally in both patient 
and control groups (11.82% vs. 11.83%). Significant distribution disequilibrium of the 
combined genotypes, 677CT+TT/1298AA (OR=0.700, P<O.OOl) and 
677CC/1298AC+CC (OR=l.205, P=0.048) were detected in MI patients. In contrast, the 
combined genotype for both variant alleles, 677CT+TT/1298AC+CC, showed a trend 
toward increased frequency in MI patients (OR: 1.221, 95% CI 0.995-1.498, P=0.056). 
To further characterize the interaction between the 677T and 1298C, all possible 
combined genotypes between the 667AIT and 1298NC were calculated at the haplotype 
level. The estimated haplotype frequencies for all four possible genotypes in both MI 
patient and control populations are presented in the table 5. The 677T-1298A haplotype 
shows significantly reduced frequency in the MI patients compared with the controls 
(OR: 0.782; 95% CI 0.685-0.894; P<O.OOl). In contrast, the 677T-1298C haplotype had 
a significantly increased frequency in the MI patients compared with the controls (OR: 
3.206; 95% CI 1.956-5.255; P<O.OOI). However, the frequencies of the cis 677C-1298C 
were similar in both patients and controls. 
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Table 5: MTHFR genotype distributions and haplotypes frequency estimation in MI 
patient and NC populations 
Genotype MI NC OR ( 95%CI) P value (n = 1032) (n = 1014) 
677CC 46.80% 42.70% 
CT 43.22% 45.36% 0.917(0.770,1.091) 0.328 
TT 9.98% 11.93% 0.818(0.619,1.081) 0.157 
CT+TT 53.20% 57.30% 0.847(0.711,1.009) 0.062 
1289 AA 39.63% 47.34% 
AC 48.93% 42.31% 1.307(1.098, 1.556) 0.003 
cc 11.43% 10.36% 1.118(0.846, 1.477) 0.434 
AC+CC 60.37% 52.66% 1.369(1.149,1.632) <0.001 
Combined genotY_Qes 
677CC/1298AA 11.82% 11.83% 0.999 (0. 764, 1.306) 
677CC /1298AC+CC 34.98% 30.6% 1.205(1.002,1.449) 0.048 
677CT+TT/1298AA 27.81% 35.51% 0. 700(0.580,0.844) <0.001 
677CT+TT/1298AC+CC 25.39% 21.80% 1.221 (0.995, 1.498) 0.056 
Ha:QlOtY.Qe freguencies 
677C-1298A 35.74% 34.93% 1.038 (0.913, 1.180) 0.572 
677T-1298A 28.36% 33.58% 0. 782 (0.685, 0.894) <0.001 
677C-1298C 32.67% 30.46% 1.106 (0.970, 1.262) 0.133 
677T-1298C 3.23% 1.05% 3.206 (1.956, 5.255) <0.001 
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Table 6. Distribution of MTHFR genotypes among MI patients with different onset age 
compared with age and gender matched NC. 
MI NC OR ( 95%CI) P value 
Age<50 
677 cc 70/139 (50.36%) 260/608 (42.76%) 
CT+TT 69/139 (49.64%) 348/608 (57.24%) 0. 736 (0.509, 1.065) 0.104 
1298 AA 62/139 (44.60%) 281/608 (46.22%) 
AC+CC 77/139 (55.40%) 327/608 (53.78%) 1.067 (0.737, 1.546) 0.731 
Age>50 
677 cc 413/893 (46.25%) 173/406 (42.61 %) 
CT+TT 480/893 (53. 75%) 233/406 (57.39%) 0.863 (0.681, 1.093) 0.222 
1298 AA 347/893 (38.86%) 199/406 (49.01%) 
AC+CC 546/893 (61.14%) 207/406 (50.99%) 1.513 (1.194, 1.916) 0.001 
Males 
677 cc 304/640 (47.50%) 201/477 (42.14%) 
CT+TT 336/640 (52.50%) 276/477 (57.86%) 0.805 (0.634, 1.022) 0.075 
1298 AA 260/640 (40.63%) 228/477 (47.80%) 
AC+CC 380/640 (59.37%) 249/477 (52.20%) 1.338 (1.054, 1. 700) 0.017 
Females 
677 cc 179/392 (45.66%) 232/537 (43.20%) 
CT+TT 213/392 (54.34%) 305/537 (56.80%) 0.905 (0.697, 1.176) 0.456 
1298 AA 149/392 (38.01 %) 252/537 (46.93%) 
AC+CC 243/392 (61.99%) 285/537 (53.07%) 1.442 (1.106, 1.880) 0.007 
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Influence of gender and onset age 
The distributions of the two MTHFR variants were further analyzed by sub-grouping 
patients and controls according to age and sex {Table 6). In the age based population 
study, the MI patients were divided into those with an early age of onset (:S 50 years) and 
those with a later age of onset (>50 years). The control population was also divided into 
the two corresponding age groups. There was no significant distribution disequilibrium 
of the 677T in either early onset or later onset patient populations. The 1298C allele 
(AC+CC) showed a significant MI risk only in the late onset MI patients compared with 
the age matched controls (OR: 1.513, 95% CI 1.194-1.916; P = 0.001). In the sex based 
population study, the 1298C allele (AC+CC) showed distribution disequilibrium in both 
male (OR: 1.338, 95% CI 1.054-1.700; P = 0.017) and female MI patients (OR: 1.442, 
95% CI 1.106-1.880; P = 0.007). 
Discussion 
Investigation of the suspected weak genetic effects, such as, MTHFR 677T and 1298C, 
require large study populations to obtain sufficient statistical power and identify possible 
allele-allele interactions. Using a genetically isolated population for study subjects can 
reduce the diversity of genetic and/or environmental modifiers. The present case-control 
study was carried out in large population including! 032 MI patients and 1014 healthy 
controls from a genetically isolated Newfoundland population. As a fact of geographic 
isolation, Newfoundland has had very little inward migration and living habits are 
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relatively similar within the population. All these make the Newfoundland population 
ideal for examination of association and co-effects of allele-allele interactions. Both 
MTHFR variants 677T and 1298C are prevalent in the Newfoundland population making 
this population of great advantage in the present study. 
In the present study, the 677T allele (CT and TT) showed a trend toward reduced 
prevalence in the MI patients compared with controls (OR: 0.847, P = 0.062) and 
evidence of a gene dosage effect for 677T. This trend is more clearly seen in the 
combined genotype analysis, in which 677CT+TT/1298AA had a significantly reduced 
prevalence in patients compared with the controls (OR: 0.700, P<O.OOI). This suggests 
that an independent but weak protective role of the 677T allele in MI. In contrast with 
677T, 1298C (AC and CC) presents a significantly increased prevalence in patients 
compared with controls (OR: 1.369, P<O.OOl). This result was supported by distribution 
disequilibrium of the combined genotype, 677CC/1298AC+CC (OR: 1.205, P = 0.048), 
in the MI patient population. Therefore, the 1298C allele is thought to be an independent 
risk factor for MI. Further analysis of these two gene variants by sub-grouping patients 
and controls according to age and sex associated 1298C with later onset MI in both 
males and females. This suggests that the 1298C allele may be more important for later 
onset MI without sex specific influence. 
Genetic predisposition in a multifactorial disease, such as MI, results from the co-effect 
of multiple genes, gene-gene and/or gene-environment interactions. These collectively 
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produce an additive or synergistic effect which affects risk for disease. Individual genetic 
changes may produce small or insufficient effects to impart significant pathogenic risk. 
Gene-gene interaction as a significant factor in genetic predisposition for MI has been 
clearly demonstrated in our previous studies (Butt et al. 2003; Xie et al. 2003), and 
genetic predisposition for CAD from co-effect of intragenic allelic interaction has also 
been previously reported for other genes (Rodriguez-Esparragon et al. 2005). In the 
present study, the 677T and 1298C variants showed independent but opposing effects on 
MI. Although the combined genotype, 677CT+TT/1298AC+CC, showed a trend to 
increased prevalence in patients compared with the controls, the difference failed to 
achieve statistical significance (OR; 1.221, P= 0.056). This reveals a potential co-effect 
of cancelling out by opposing effects from allele-allele interaction between 677T and 
1298C. 
The suggested allele-allele interaction was further characterized by calculating the 
estimated haplotype frequencies for all possible haplotypes. Interestingly, there was a 
significantly increased frequency of the 677T-1298C haplotype (OR=3.206, P<O.OOl), 
but not 677C-1298C (OR=l.l06, P=0.133), in the MI patients compared with the 
controls. This suggested that the co-effect of cancelling out due to the interactions 
between 677T and 1298C occurs when the two alleles are in trans. The protective effect 
of 677T seem to be silenced when it is in cis with 1298C. The identified intragenic allelic 
interactions between 677T and 1298C may have also influenced results of previous 
association studies showing discordant results. 
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The cis 677T-1298T haplotype is extremely rare (0.0032 to 0.0034) based on a meta-
analysis which calculated the halotype :frequencies in pooled European, Australian and 
North America populations (Ogino and Wilson 2003). In the present study, the 
Newfoundland population showed much higher frequencies of the combined genotype of 
677CT+TT/1298AC+CC than other population (Ogino and Wilson 2003). Therefore, it 
is not surprising to find a higher :frequency for cis 677T-1298T in patients (0.0323) and 
controls (0.0105). This is possible due to a founder effect. A similar a high :frequencie of 
cis 677T-1298T has also been reported from other studies (Isotalo and Donnelly 2000; 
Isotalo et al. 2000; Dekou et al. 2001). 
A similar case control study was reported from a German group (Kolling et al. 2004). In 
this study, the 677T and the 1298C were genotyped in 2,121 angiographic CAD patients 
and 617 controls which were collected from consecutive Caucasian patients with normal 
coronary angiograms and without ventricular wall motion abnormalities. The two 
variants were not associated with the presence of angiographic CAD in this study. 
Comparing this study with ours, there are several differences which may affect outcome. 
1) The control population in the German study was small compared with the case 
population (617 vs. 2,121); 2) The case and control populations in the German study 
were collected mainly from the southern part of Germany, Munchen area, close to 
Austria, Switzerland and Liechtenstein. The effect of ethnic diversity and existence of 
different ethnic specific genetic modifiers would potentially complicate results. 3) 
69 
Environmental effects, such as diets, may be different in the two studied populations; 4) 
The targeted clinical conditions in the two studies are different. The angiographic CAD 
used in the German study is an earlier event in atherosclerosis that may or may not 
progress to atherothrombosis (MI). It is presently not clear at which stage MTHFR 667T 
and 1298C are involved. If the two variants are involved in late events in the 
pathogenesis of MI, different outcomes between the two studies are not surprising. 
The 667T and 1298C have been previously shown to affect folate metabolism and 
plasma homocysteine levels (Brattstrom et al. 1998; Friedman et al. 1999). Moreover, the 
association between MTHFR genotype and bone phenotypes depending on plasma folate 
status have also been reported (McLean et al. 2003; Abrahamsen et al. 2006). The design 
of the present study did not permit a comparison of the genotypes with biochemical 
parameters, or other factors, like smoking, diabetes and hypertension. Data on folic acid 
taken in the studied population are also not available. It is possible that other unidentified 
genetic or environmental factor may also be involved in modification of the effect of 
677T and/or 1298C, and the co-effect of the allele-allele interaction. Further studies are 
planed in this area to elucidate the relationship with biochemical risk factors and other 
environmental factors mentioned above. 
In summary, we performed a large case control association study using the genetically 
isolated Newfoundland population to investigate the correlation between two MTHFR 
common variants, 677C>T and 1298A>C, and the risk for MI. Our results suggest 
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independent but opposite roles of MTHFR 677T and 1298C in MI. The MTHFR 677T 
allele presents an independent protective role against MI. In contrast, the MTHFR 1298C 
is an independent risk factor for MI which may mainly predisposes for later onset MI. 
The results from the combined genotype analysis and estimated haplotype frequency 
calculation suggest the existence of complicated allele-allele interaction between 677T 
and 1298C. A co-effect of cancelling out effects through interactions between 677T and 
1298C may occur mainly when the two alleles are in trans, and the protective effect of 
677T may be silenced when the it is in cis with 1298C. The identified intragenic allelic 
interactions between 677T and 1298C may contribute to discordant results from previous 
association studies. 
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Chapter 7 
Conclusion 
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We undertook a large case control association study with 1,032 MI patients and 1,014 
healthy controls from a genetically isolated population, the Newfoundland population, to 
investigate the genetic effects of the THBS4 A387P, MTHFR 677C>T and 1298A>C 
variants in the etiology of MI. We conclude that 1) homozygosity for the THBS4 29926C 
variant is associated with MI, especially in older females. 2) the 677T is a weak 
protective factor against MI but its effect is silenced when it is in cis with 1298C; 3) the 
1298C is a risk factor for later onset MI and its effect is reduced by an in trans 677T. 
These effects may be responsible for the lack of agreement among previous association 
studies examining MTHFR gene variants in MI. 
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